OncoZenge AB (publ) (ONCOZ.ST)
SEK 3.97
(4.34%)
SEK 3.97
(4.34%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -15.9 Million SEK | 63.5% |
| 2022 | -43.56 Million SEK | -790.25% |
| 2021 | -4.89 Million SEK | -510.99% |
| 2020 | -801 Thousand SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -2.37 Million SEK | 25.31% |
| 2024 Q2 | -2.04 Million SEK | 13.54% |
| 2023 Q1 | -4.05 Million SEK | 11.02% |
| 2023 FY | -15.9 Million SEK | 63.5% |
| 2023 Q3 | -4.18 Million SEK | 6.79% |
| 2023 Q2 | -4.49 Million SEK | -10.83% |
| 2023 Q4 | -3.17 Million SEK | 24.22% |
| 2022 Q4 | -4.55 Million SEK | -42.03% |
| 2022 FY | -43.56 Million SEK | -790.25% |
| 2022 Q3 | -3.2 Million SEK | -13.64% |
| 2022 Q2 | -2.82 Million SEK | 91.44% |
| 2022 Q1 | -32.98 Million SEK | -2300.66% |
| 2021 Q3 | -987 Thousand SEK | 10.92% |
| 2021 Q2 | -1.1 Million SEK | 22.25% |
| 2021 Q1 | -1.42 Million SEK | 0.0% |
| 2021 Q4 | -1.37 Million SEK | -39.21% |
| 2021 FY | -4.89 Million SEK | -510.99% |
| 2020 FY | -801 Thousand SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 93.613% |
| Ziccum AB (publ) | -21.56 Million SEK | 26.243% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | 3.042% |
| BioArctic AB (publ) | 252.64 Million SEK | 106.294% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -1781.893% |
| Mendus AB (publ) | -100.65 Million SEK | 84.201% |
| Genovis AB (publ.) | 54.22 Million SEK | 129.326% |
| Intervacc AB (publ) | -93.57 Million SEK | 83.007% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -2.514% |
| Active Biotech AB (publ) | -46.48 Million SEK | 65.79% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 188.3% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | 71.305% |
| Aptahem AB (publ) | -10.1 Million SEK | -57.371% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 95.054% |
| Kancera AB (publ) | -65.04 Million SEK | 75.551% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 88.187% |
| Fluicell AB (publ) | -26.87 Million SEK | 40.839% |
| Saniona AB (publ) | -81.06 Million SEK | 80.384% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -28.543% |
| Biovica International AB (publ) | -126.07 Million SEK | 87.387% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | 62.588% |
| AcouSort AB (publ) | -17.48 Million SEK | 9.064% |
| Xintela AB (publ) | -57.23 Million SEK | 72.218% |
| Abliva AB (publ) | -96.54 Million SEK | 83.529% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 95.104% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -353.695% |
| Amniotics AB (publ) | -29.07 Million SEK | 45.303% |
| 2cureX AB (publ) | -36.36 Million SEK | 56.269% |
| CombiGene AB (publ) | -36.3 Million SEK | 56.199% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | -8.62% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 95.863% |
| Camurus AB (publ) | 532.35 Million SEK | 102.987% |
| Corline Biomedical AB | -1.78 Million SEK | -789.374% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 91.203% |
| Isofol Medical AB (publ) | -41.68 Million SEK | 61.85% |
| I-Tech AB | 24.43 Million SEK | 165.079% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 97.983% |
| Cyxone AB (publ) | -21.66 Million SEK | 26.587% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | 84.993% |
| Biosergen AB | -27.26 Million SEK | 41.676% |
| Cantargia AB (publ) | -290.01 Million SEK | 94.517% |
| NextCell Pharma AB | -43.17 Million SEK | 63.166% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 91.203% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | 6.986% |
| Nanologica AB (publ) | -69.96 Million SEK | 77.271% |
| SynAct Pharma AB | -224.49 Million SEK | 92.917% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | 64.003% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | 33.615% |
| LIDDS AB (publ) | -40.67 Million SEK | 60.904% |
| Lipum AB (publ) | -37.25 Million SEK | 57.315% |
| BioInvent International AB (publ) | -369.94 Million SEK | 95.701% |
| Alzinova AB (publ) | -16.52 Million SEK | 3.753% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 93.726% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -148.731% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | 86.181% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | 21.039% |
| Simris Alg AB (publ) | -36.63 Million SEK | 56.593% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 89.15% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 94.877% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | 85.663% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -37.489% |